1241TiPJAVELIN PARP medley: A phase Ib/II study of avelumab (anti–PD-L1) plus talazoparib in locally advanced or metastatic solid tumors. (23rd October 2018) - Yap, T A; Beck, J T; Stewart, R A; Dahm, S C; Chappey, C; Cesari, R; Scheuber, A; Galsky, M D; Wise, D